CN114732894A - Application of Perilipin1 in preparation of diabetic nephropathy product - Google Patents
Application of Perilipin1 in preparation of diabetic nephropathy product Download PDFInfo
- Publication number
- CN114732894A CN114732894A CN202210456301.XA CN202210456301A CN114732894A CN 114732894 A CN114732894 A CN 114732894A CN 202210456301 A CN202210456301 A CN 202210456301A CN 114732894 A CN114732894 A CN 114732894A
- Authority
- CN
- China
- Prior art keywords
- perilipin1
- diabetic nephropathy
- application
- preparation
- renal function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000017795 Perilipin-1 Human genes 0.000 title claims abstract description 23
- 108010067162 Perilipin-1 Proteins 0.000 title claims abstract description 23
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 19
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 8
- 206010020880 Hypertrophy Diseases 0.000 claims description 4
- 230000001434 glomerular Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 10
- 230000001276 controlling effect Effects 0.000 abstract description 9
- 230000003907 kidney function Effects 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 230000036772 blood pressure Effects 0.000 abstract description 5
- 235000005911 diet Nutrition 0.000 abstract description 5
- 230000037213 diet Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000007423 decrease Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 210000005086 glomerual capillary Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of diabetic nephropathy. The invention provides an application of Perilipin1 in preparing a diabetic nephropathy product. The experimental result of the invention shows that the Perilipin1 can obviously relieve the renal function injury of diabetes and the renal function decline. The using effect of the health-care food is far better than the common regulating methods of controlling blood sugar, controlling blood pressure, regulating diet and the like. No need of operation, low cost and excellent use effect.
Description
Technical Field
The invention relates to the technical field of diabetic nephropathy, in particular to application of Perilipin1 in preparation of diabetic nephropathy products.
Background
Diabetic nephropathy is the progressive reduction in proteinuria and glomerular filtration rate due to prolonged diabetes. Diabetic nephropathy is one of the most important complications for diabetic patients. The incidence of diseases in China also tends to rise, and the disease becomes the leading cause of chronic kidney diseases. Due to the existence of complex metabolic disorder, the treatment of the kidney disease is more troublesome once the kidney disease reaches the terminal stage than the treatment of other kidney diseases, so the timely prevention and treatment of the kidney disease is significant for delaying the diabetic nephropathy.
At present, the commonly used method for controlling diabetic nephropathy mainly focuses on controlling blood sugar, controlling blood pressure, adjusting diet, organ transplantation and the like, the blood sugar, the blood pressure, the diet and the like can only play a role in regulation, and although the organ transplantation has a good effect, the cost is high, a proper kidney source needs to be matched, and the conditions are very harsh. How to develop a new way for treating diabetic nephropathy becomes an urgent problem to be solved.
Disclosure of Invention
The invention aims to provide application of Perilipin1 in preparation of diabetic nephropathy products, and develops a new way for treating diabetic nephropathy.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides an application of Perilipin1 in preparing a diabetic nephropathy product.
The invention also provides application of Perilipin1 in preparation of a product for relieving glomerular hypertrophy.
The invention provides an application of Perilipin1 in preparation of a diabetic nephropathy product. The experimental result of the invention shows that the Perilipin1 can obviously relieve the renal function injury of diabetes and the renal function decline. The using effect of the health-care food is far better than the common regulating methods of controlling blood sugar, controlling blood pressure, regulating diet and the like. No need of operation, low cost and excellent use effect.
Drawings
FIG. 1 shows the effect of Perilipin1 on the serum urea nitrogen content of mice;
FIG. 2 is a graph showing the effect of Perilipin1 on the urinary albumin/creatinine ratio in mice;
FIG. 3 is the effect of Perilipin1 on the area of a loop of a glomerular capillary in a mouse;
FIG. 4 is a graph showing the effect of Perilipin1 on the percentage of mouse mesenteric region area;
FIG. 5 is a pathological staining of mouse kidney tissue HE.
Detailed Description
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Test plasmids:
a Perilipin1 overexpression plasmid (pPLIN1) purchased from Ebos;
pcDNA3 plasmid served as a control.
Test animals:
c57BL/6J mice, male, 8 weeks old, 24 in total. Mice were divided into four groups of 6 mice, numbered pcDNA3 control (pcDNA3 Con), pcDNA3 test (pcDNA3 DM), pPLIN1 control (pPLIN1 Con) and pPLIN1 test (pPLIN1 DM).
Example 1 establishment of diabetes model
Injecting Streptozotocin (STZ)120mg/kg body weight into tail vein of mice of pcDNA3 test group and pPLIN1 test group, collecting venous blood of the mice of the two groups the next day, and measuring that the blood sugar is higher than 16.7mmol/L, namely successfully molding.
Example 2 inoculation of Perilipin1 overexpression plasmid
After the success of the diabetic mouse model, the pPLIN1 test group and the pPLIN1 control group were injected with pPLIN1 in the tail vein at a dose of 1mg/kg body weight, followed by injection every 14 days; the pcDNA3 test group and the pcDNA3 control group were injected with pcDNA3 using the same method and dose, mice were sacrificed 3 months later, and mouse specimens were collected from the pcDNA3 test group, the pcDNA3 control group, the pPLIN1 test group and the pPLIN1 control group.
And (4) detecting a result: detecting the serum urea nitrogen content, urine albumin/creatinine ratio, the area of the loop of the glomerular capillary and the area percentage of the mesentery of mouse samples of a pcDNA3 test group, a pcDNA3 control group, a pPLIN1 test group and a pPLIN1 control group, wherein the results are shown in figures 1-4; the results of HE pathological staining of mouse kidney tissue are shown in fig. 5.
And (4) conclusion:
the results of fig. 1 show that: the serum urea nitrogen content (BUN) of the diabetic mice is increased, which indicates that the renal function is reduced; overexpression of Perilipin1 can relieve diabetic renal function injury.
The results of fig. 2 show that: an increase in urine albumin/creatinine ratio (ACR) in the urine of diabetic mice suggests the presence of diabetic nephropathy; overexpression of Perilipin1 ameliorates diabetic nephropathy.
The results of FIGS. 3-5 show that: enlargement of the diabetic glomerular capillary loop and mesangial region suggests glomerular hypertrophy; overexpression of Perilipin1 ameliorated glomerular hypertrophy.
From the above examples, the present invention provides the use of Perilipin1 in the preparation of diabetic nephropathy products. The experimental result of the invention shows that the Perilipin1 can obviously relieve the renal function injury of diabetes and the renal function decline. The using effect of the health-care food is far better than the common regulating methods of controlling blood sugar, controlling blood pressure, regulating diet and the like. No need of operation, low cost and excellent use effect.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (2)
- Application of Perilipin1 in preparation of diabetic nephropathy products.
- Use of Perilipin1 in the manufacture of a product for alleviating glomerular hypertrophy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210456301.XA CN114732894B (en) | 2022-04-28 | 2022-04-28 | Application of Perilipin1 in preparation of diabetic nephropathy products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210456301.XA CN114732894B (en) | 2022-04-28 | 2022-04-28 | Application of Perilipin1 in preparation of diabetic nephropathy products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114732894A true CN114732894A (en) | 2022-07-12 |
| CN114732894B CN114732894B (en) | 2023-10-27 |
Family
ID=82282663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210456301.XA Active CN114732894B (en) | 2022-04-28 | 2022-04-28 | Application of Perilipin1 in preparation of diabetic nephropathy products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114732894B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115575534A (en) * | 2022-09-30 | 2023-01-06 | 南京医科大学第二附属医院 | Application of isovaleric acid as marker in preparation of kit for detecting diabetic nephropathy and kit for detecting diabetic nephropathy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013133390A1 (en) * | 2012-03-08 | 2013-09-12 | タカノ株式会社 | Anti-nephropathic drug |
| CN105769848A (en) * | 2016-03-28 | 2016-07-20 | 昆明医科大学 | Application of norathyriol in preparation of medicaments and health-care products for preventing and treating chronic kidney disease |
| CN113244406A (en) * | 2021-05-10 | 2021-08-13 | 清华大学 | Use of agents for the manufacture of a medicament |
-
2022
- 2022-04-28 CN CN202210456301.XA patent/CN114732894B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013133390A1 (en) * | 2012-03-08 | 2013-09-12 | タカノ株式会社 | Anti-nephropathic drug |
| CN105769848A (en) * | 2016-03-28 | 2016-07-20 | 昆明医科大学 | Application of norathyriol in preparation of medicaments and health-care products for preventing and treating chronic kidney disease |
| CN113244406A (en) * | 2021-05-10 | 2021-08-13 | 清华大学 | Use of agents for the manufacture of a medicament |
Non-Patent Citations (2)
| Title |
|---|
| HIDEYUKI OKUMA等: "Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice", MDPI, vol. 22, no. 14, pages 1 - 13 * |
| 卫兵艳，等: "周脂素在糖尿病肾病大鼠肾组织中的表达", 中国实验动物学报, vol. 27, no. 3, pages 347 - 352 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115575534A (en) * | 2022-09-30 | 2023-01-06 | 南京医科大学第二附属医院 | Application of isovaleric acid as marker in preparation of kit for detecting diabetic nephropathy and kit for detecting diabetic nephropathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114732894B (en) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mizuno et al. | Suppressions of chronic glomerular injuries and TGF-β1 production by HGF in attenuation of murine diabetic nephropathy | |
| Vaziri | Erythropoietin and transferrin metabolism in nephrotic syndrome | |
| CN114732894A (en) | Application of Perilipin1 in preparation of diabetic nephropathy product | |
| CN110248646A (en) | Slow releasing composition comprising pirfenidone is used to treat and reverse the medicinal usage of people's steatohepatitis (NAFLD/NASH) | |
| AU4023501A (en) | Treatment of diabetic nephropathy and microalbuminuria | |
| WO2021017434A1 (en) | Application of acanthopanax trifoliatus polysaccharide atp1-1 in preparation of medicines for treating diabetes | |
| JPH07503471A (en) | Growth factor compositions, preparation methods and uses | |
| Jain et al. | Systematic review of the impact of genistein on diabetes-related outcomes | |
| YOKOZAWA et al. | Effects of ginseng in nephrectomized rats | |
| TWI571258B (en) | Medicament for regulating blood glucose levels | |
| Patel et al. | Roflumilast alleviates adenine-induced chronic kidney disease by regulating inflammatory biomarkers | |
| WO2018166494A1 (en) | Use of matrine derivative in treatment of diabetes mellitus | |
| US20210052564A1 (en) | Use of pantoprazole in prevention and treatment of nonalcoholic fatty liver disease | |
| Cui et al. | Alleviative effect of ciliary neurotrophic factor analogue on high fat‐induced hepatic steatosis is partially independent of the central regulation | |
| CN107007821A (en) | Interleukin Ⅲ 8 is preparing the application in preventing and treating obesity and metabolic syndrome product | |
| CN113332395A (en) | Traditional Chinese medicine composition for treating type 2 diabetes and preparation method thereof | |
| CN114246866B (en) | Medicine for treating chronic kidney disease and application thereof | |
| Norton | Affect of serum leptin on nutritional status in renal disease | |
| Christiansen et al. | Enhancement of glomerular filtration rate and renal plasma flow by oral glucose load in well controlled insulin-dependent diabetics | |
| Poli et al. | Modulation of hepatic fibrogenesis by antioxidants | |
| US20160235690A1 (en) | Effect of garcinol in delaying the progression of diabetic nephropathy | |
| EP0997146A1 (en) | A drug for treating diabetic nephrosis and delaying renal failure | |
| WO2017193900A1 (en) | Poria cocos skin extract, poricoic acid a, and poricoic acid b and application thereof for blood sugar modulation | |
| CN108836974B (en) | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism | |
| Huang et al. | The intervention effects of AdipoRon on renal injury in type 2 diabetic mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |